This study, called TARGET-ASPECT, looks at patients who had a type of stroke called acute ischemic stroke and were treated with clot-busting medicine and a procedure to remove the clot. Even with these treatments, about half of patients don't fully recover. The study aims to see if certain brain imaging scores, especially when combined, can better predict how well patients will recover 90 days after their stroke and if their blood vessels reopen successfully. The study will include 152 patients and last about 9 months. The goal is to find easy and reliable tools that doctors can use to make better treatment decisions.
Patients aged 18 years or older
Confirmed acute ischemic stroke on imaging
Treated with both thrombolysis and thrombectomy
Clinical follow-up data available at 90 days (mRS score)
Primary hemorrhagic stroke
Early death or loss to follow-up without evaluation
Poor-quality imaging that cannot be analyzed
The study population consists of adult patients (aged 18 and over) who have experienced an acute ischemic stroke confirmed by imaging. These patients have undergone combined treatment with thrombolysis (clot-busting medication) and thrombectomy (mechanical clot removal). They are selected from a single medical center where detailed clinical and imaging follow-up data, including functional outcomes at 90 days, are available. Participants must have adequate-quality imaging and not have experienced early death or loss to follow-up before evaluation.
Cohort
Retrospective
Not listed
Favorable functional outcome defined as a mRS score of 0 to 2 at 90 days
Click on the lead sponsor to view all of their trials.
